ANI Pharmaceuticals Announces ~$560M Recommended Cash Offer to Acquire Egetis Therapeutics

Shots: ANI Pharmaceuticals has announced a recommended public cash offer to acquire Egetis Therapeutics for SEK 11.25/share (27% premium to the 60-day VWAP), valuing the offer at ~SEK 5.6B (~$560M); EV ~$434M after adjusting for Egetis’ $190M Rare Pediatric Disease PRV sale Deal adds Emcitate (tiratricol), the first & only approved therapy in the US & EU for peripheral thyrotoxicosis in MCT8 deficiency (Allan–Herndon–Dudley syndrome); ANI estimates >$300M peak sales potential with exclusivity/patent protection into 2045 Egetis’ Board unanimously recommends the offer; shareholders holding ~42% of shares have undertaken to accept; acceptance window expected ~Nov 20–Dec 18, 2026, subject to >90% tender & customary regulatory clearances Ref: ANI Pharmaceuticals  |   Image: ANI Pharmaceuticals & Egetis Therapeutics  |  Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post ANI Pharmaceuticals Announces ~$560M Recommended Cash Offer to Acquire Egetis Therapeutics appeared first on PharmaShots.